Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758168 | 0.80 | KMT2A (0.49) | MEN1KMT2ATSHRALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL192474 | 0.79 | KMT2A (0.48) | MEN1KMT2ATSHRALDH1A1CYP3A4 | |
| Bromide SCHEMBL9320690 | 0.79 | KMT2A (0.48) | MEN1KMT2ATSHRALDH1A1CYP3A4 | |
| Iodide SCHEMBL1255392 | 0.79 | TSHR (0.57) | MEN1KMT2ATSHRALDH1A1CYP2C9 | |
| Chloromethane SCHEMBL10796929 | 0.77 | TSHR (0.55) | MEN1KMT2ATSHRALDH1A1CYP2C9 | |
| SCHEMBL758619 | 0.77 | TSHR (0.59) | MEN1KMT2ATSHRALDH1A1CYP2C9 | |
| SCHEMBL22972950 | 0.76 | TSHR (0.41) | MEN1KMT2ATSHRALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL204258 | 0.76 | TSHR (0.57) | MEN1KMT2ATSHRALDH1A1 | |
| Fluoride Ion SCHEMBL1254970 | 0.76 | TSHR (0.57) | MEN1KMT2ATSHRALDH1A1CYP2C9 | |
| Bromide SCHEMBL1254317 | 0.76 | TSHR (0.57) | MEN1KMT2ATSHRALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1852133-A2 | Compositions with enhanced antimicrobial efficacy against acanthamoebae | BAUSCH & LOMB INCORPORATED (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1817059-A2 | CONJUGATES OF 1,8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY | Genentech, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2006060533-A2 | CONJUGATES OF 1, 8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY | GENENTECH, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | MEN1 1674/4885KMT2A 1301/4885TSHR 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.